Mylan's EpiPen Boosted as FDA Sees Holes in Teva ApplicationBy
Teva expects its injection will be `significantly delayed'
Israel drugmaker will submit response to U.S. agency
Mylan NV may be able to curtail a decline in future sales of its EpiPen allergy-reaction injector after the U.S. Food and Drug Administration identified “major deficiencies” in an application for a competing generic version from Teva Pharmaceutical Industries Ltd.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Gulf of Mexico Oil Spill May Be Largest Since 2010 BP Disaster
- Airbus Snaps Up Bombardier Jet in New Challenge to Boeing
- Billionaire Tom Barrack Throws Harvey Weinstein a Lifeline